<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103215</url>
  </required_header>
  <id_info>
    <org_study_id>KMUHIRB-F(I)-20210157</org_study_id>
    <nct_id>NCT05103215</nct_id>
  </id_info>
  <brief_title>Lidocaine Infusion With ANI Monitoring in Spine Surgery.</brief_title>
  <official_title>The Analgesic Effect of Intravenous Lidocaine Infusion in Combination of Analgesia Nociception Index Monitoring in Spine Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the analgesic effect of intraoperative continuous lidocaine infusion (1.5 mg/kg/h&#xD;
      (ideal body weight)) in combination of analgesia nociception index and depth of anesthesia&#xD;
      monitors guided anesthetics adjustment on enhanced recovery after surgery (ERAS) in patients&#xD;
      undergoing elective lumbar spine surgery (≥2 sessions).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients undergoing elective lumbar spine surgery (≥2 sessions) are randomly assigned and&#xD;
      divided patients into two groups according to the allocation sequence table (corresponding to&#xD;
      1:1 randomization) generated by the computer. Patients in the lidocaine group receive an&#xD;
      intravenous injection of 1.5 mg/kg lidocaine at induction of anesthesia and continuous&#xD;
      infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after&#xD;
      operation. Patients in control group receive the same volume of saline injection. During the&#xD;
      operation, the dose of anesthetic drugs (propofol, remifentanil and rocuronium) are adjusted&#xD;
      to maintain the mean arterial pressure and heartbeat fluctuations within 20% of the baseline&#xD;
      value, Entropy (or BIS) value at 40-60, and ANI at 50-70 in both groups. The pain score&#xD;
      (numerical rating scale), cumulative amount of opioids used after the operation within 3&#xD;
      days, and the quality of recovery on the third day after the operation are recorded and&#xD;
      analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 3, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative amount of opioids used</measure>
    <time_frame>within 48 hours after operation</time_frame>
    <description>cumulative amount of opioids used after the operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the quality of recovery after the operation</measure>
    <time_frame>on the third day after the operation</time_frame>
    <description>Quality of recovery-15 score, QoR-15, 0-150, higher score means better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain score</measure>
    <time_frame>within 72 hours after operation</time_frame>
    <description>numerical rating scale, NRS, 0-10, higher score means worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cumulative amount of opioids used</measure>
    <time_frame>within 72 hours after operation</time_frame>
    <description>cumulative amount of opioids used after the operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative amount of propofol used</measure>
    <time_frame>during operation</time_frame>
    <description>cumulative amount of propofol used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative amount of remifentanil used</measure>
    <time_frame>during operation</time_frame>
    <description>cumulative amount of remifentanil used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative amount of rocuronium used</measure>
    <time_frame>during operation</time_frame>
    <description>cumulative amount of rocuronium used</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Spine Surgery</condition>
  <arm_group>
    <arm_group_label>lidocaine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the lidocaine group receive an intravenous injection of 1.5 mg/kg Lidocaine HCl 2% at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in control group receive the same volume of saline injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine HCl 2%</intervention_name>
    <description>Intravenous injection of 1.5 mg/kg lidocaine at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.</description>
    <arm_group_label>lidocaine group</arm_group_label>
    <other_name>Xylocaine Injection 2%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Intravenous injection of 1.5 mg/kg normal saline at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>0.9% Normal Saline (20mL)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Twenty to eighty-year-old&#xD;
&#xD;
          2. ASA class I-III patients undergoing&#xD;
&#xD;
          3. Elective lumbar spine surgery under general anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to understand the Numerical Rating Scale (NRS)&#xD;
&#xD;
          2. Severe mental disorder&#xD;
&#xD;
          3. Poor liver function&#xD;
&#xD;
          4. Pregnant or lactating women&#xD;
&#xD;
          5. Morbidly obese&#xD;
&#xD;
          6. History of epilepsy or allergy to any of the drugs used in this study&#xD;
&#xD;
          7. Current use of opioids&#xD;
&#xD;
          8. Baseline heart rate &lt;50 beats/min&#xD;
&#xD;
          9. Arrhythmia history with cardiac rhythm device&#xD;
&#xD;
         10. Body weight &lt;40 kg and &gt;80kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-Fu Wu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan (R.O.C.)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhi-Fu Wu, MD</last_name>
    <phone>07-3121101</phone>
    <phone_ext>7035</phone_ext>
    <email>aneswu@gmail.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lidocaine, enhanced recovery after surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

